Abstract. The β 2 -adrenergic receptor (β 2 -AR, encoded by the ADRB2 gene) is a member of the G-protein-coupled receptor superfamily that can be stimulated by catecholamines. Studies in vivo and in vitro have confirmed that β-blockers (β-AR antagonists) exert antitumor effects on various tumors. Furthermore, ADRB2 single-nucleotide polymorphisms (SNPs) have been identified to alter the expression and conformation of β 2 -AR, which may alter the β-blocker drug response. The aim of the present study was to investigate the effect of β-blockers on triple-negative breast cancer cells and determine whether ADRB2 SNPs affect the response to β-blocker drugs. Propranolol and ICI 118,551 significantly inhibited the viability of MDA-MB-231 cells, arrested cell cycle progression at G 0 /G 1 and S phase and induced cell apoptosis. Western blot analysis indicated that the phosphorylation levels of extracellular-signal-regulated kinase (ERK)1/2 and the expression levels of cyclo-oxygenase 2 (COX-2) were significantly decreased following β-blocker treatment. Four haplotypes, which comprised ADRB2 SNPs rs1042713 and rs1042714, were transfected into 293 cells. After 24 and 48 h of transfection, ADRB2 mRNA expression was significantly decreased in mutant groups compared with the wild-type group. The ADRB2 SNPs exerted no effect on cell viability, but did affect the drug response of ICI 118,551. Furthermore, ADRB2 SNPs also affected the regulatory function of ICI 118,551 on the ERK/COX-2 signaling pathway. Collectively, propranolol and ICI 118,551 inhibited the viability of MDA-MB-231 cells by downregulating the ERK/COX-2 signaling pathway and inducing apoptosis. The results of the present study indicated that SNPs rs1042713 and rs1042714 of ADRB2 affected the response to ICI 118,551, and the underlying molecular mechanism was elucidated.
Introduction
Breast cancer is the most frequently diagnosed cancer among women worldwide, and between 12 and 17% of female patients are diagnosed with triple-negative breast cancer (TNBC) (1) . TNBC is characterized by the absence of estrogen receptor (ER), progesterone receptor and human epidermal growth factor receptor type 2 (HER2) expression, which means that patients with TNBC cannot be treated with endocrine therapy or therapies targeting HER2 (2) (3) (4) . Notably, conventional chemotherapy remains the principal treatment for TNBC, but is associated with a high recurrence rate (5, 6) .
Adrenergic receptors (ARs) are members of the G-protein-coupled receptor superfamily and are divided into two principal types: α and β (7) . According to function and tissue distribution, α-ARs are divided into six subtypes (α 1A , α 1B , α 1D , α 2A , α 2B and α 2C ), whereas β-ARs are divided into three subtypes (β 1 , β 2 and β 3 ) (7) . Catecholamines, such as epinephrine and norepinephrine (NE), stimulate β-ARs and activate adenylate cyclase, thereby promoting the release of the second messenger 3'-5'-cyclic adenosine monophosphate, which regulates various downstream signal transduction pathways (8) . There is evidence that β-AR stimulation may promote the proliferation, metastasis, invasion and angiogenesis of tumors (9, 10) . Notably, a proof-of-principle study and two population studies have identified that patients with breast β-blockers inhibit the viability of breast cancer cells by regulating the ERK/COX-2 signaling pathway and the drug response is affected by ADRB2 single-nucleotide polymorphisms WAN cancer who were treated with β-blockers (β-AR antagonists) exhibited a significant decrease in the incidence of metastasis, cancer recurrence and cancer-specific mortality (11) (12) (13) . β-blockers are commonly used to treat cardiovascular diseases, including angina pectoris and hypertension (14, 15) . However, propranolol (a non-selective β-blocker) was identified to be effective in treating severe infantile hemangiomas and has been approved as the first-line therapy for proliferating infantile hemangioma by the US Food and Drug Administration in 2014 (16) . A number of in vitro and in vivo studies have also demonstrated the antitumor activity of β-blockers against various types of cancer, including breast (17, 18) , pancreatic (19) and prostate cancer (20) , and ovarian carcinomas (21) , melanoma (22) and neuroblastoma (23) . Işeri et al (24) identified that propranolol and ICI 118,551 (selective β 2 -blockers) inhibited the invasion and migration of non-stimulated breast cancer cells (MCF-7) in vitro. In addition, Choy et al (25) demonstrated that propranolol treatment of triple-negative brain-metastatic cells (MDA-MB-231 Br) decreased the development of brain metastases in vivo. β-blockers have been identified to be beneficial to the survival of patients with TNBC; however, the antitumor mechanism involved remains unclear.
In vitro studies have confirmed that β-ARs were markedly expressed in the human breast adenocarcinoma cell line MDA-MB-231, with β 2 -AR being the most prominent (26) . Pharmacogenomics studies have demonstrated that the polymorphisms of ADRB2, which encodes β 2 -AR, may lead to the individual differences in the treatment of asthma and cardiovascular disease (27, 28) . rs1042713 (A46G) and rs1042714 (C79G) are two classic non-synonymous single-nucleotide polymorphisms (SNPs) of ADRB2 (29) . SNP rs1042713 of ADRB2 has been identified to be associated with Tumor-Node-Metastasis grade, lymph node metastasis and 1-year survival rate of pancreatic carcinoma (30) . With regard to SNP rs1042714, Wang et al (31) identified that this polymorphism was significantly associated with the risk of lung adenocarcinoma (AC) in young subjects (aged ≤50 years). Although the association between ADRB2 SNPs and tumor development has been reported, it remains unclear whether such SNPs affect the anticancer effects of β-blockers.
The aim of the present study was to investigate the effect of β-blockers on MDA-MB-231 cells, and determine whether SNPs rs1042713 and rs1042714 of ADRB2 affect the response to ICI 118,551. Protein samples were boiled with loading buffer (SDS-PAGE Sample Loading Buffer; Beyotime Institute of Biotechnology) for 10 min, and then equal quantities of total protein (20 µg) were separated by SDS-PAGE (10% gel) and then transferred on to polyvinylidene difluoride membranes (EMD Millipore, Billerica, MA, USA). The membranes were blocked with 5% non-fat dry milk in Tris-buffered saline with 1% Tween-20 (TBST) for 2 h at room temperature and subsequently incubated overnight with primary antibodies at 4˚C. The membranes were washed three times for 30 min with TBST at room temperature, and then incubated with secondary antibodies for 1 h at room temperature. Following washing with TBST three times, the protein bands were visualized using Enhanced Chemiluminescence Prime Western Blotting Detection Reagent (GE Healthcare, Little Chalfont, UK) and semi-quantified analysis was carried out using ImageJ software (version k 1.45, National Institutes of Health, Bethesda, MD, USA).
Materials and methods

Cell
293 cells were transfected with vector control, wild-type ADRB2 and mutant ADRB2 plasmids and treated with 80 µM ICI 118,551 for 24 h. Protein extraction and western blot analysis were performed as aforementioned.
The following pr ima r y antibodies were used: Anti-extracellular-signal-regulated kinase (ERK)1/2 (dilution 1:1,000; cat. no. 9102; Cell Signaling Technology, I nc.), a nti-phospho -ER K1/2 ( T h r 2 02 / Ty r 2 0 4 ) (d i lution 1:2,000; cat. no. 9101; Cell Signaling Technology, Inc.), anti-p38 (dilution 1:1,000; cat. no. 9212; Cell Signaling Technology, Inc.), anti-phospho-p38-Thr 180 /Tyr 182 (dilution 1:1,000; cat. no. 4092; Cell Signaling Technology, Inc.), anti-cyclo-oxygenase 2 (COX-2; dilution 1:1,000; cat. no. ab62331; Abcam, Cambridge, UK) anti-β 2 -ΑR antibody (dilution 1:1,000; cat. no. ab61778; Abcam) and GAPDH (dilution 1:10,000; cat. no. AC002; ABclonal Biotech Co., Ltd., Woburn, MA, USA). The following secondary antibodies were used: Horseradish peroxidase-conjugated anti-rabbit immunoglobulin G (IgG; whole molecule) (dilution 1:10,000; cat. no. A9169; Sigma-Aldrich; Merck KGaA) and anti-mouse IgG (whole molecule) (dilution 1:10,000; cat. no. A9044; Sigma-Aldrich; Merck KGaA).
Plasmids and cell transfection. pcDNA3.1-A DR B2
(46AA/79CC; wild-type ADRB2 plasmid), pcDNA3.1-ADRB2 (46AA/79GG), pcDNA3.1-ADRB2 (46GG/79CC) and pcDNA3.1-ADRB2 (46GG/79GG) were purchased from Sangon Biotech Co., Ltd. (Shanghai, China). pcDNA3. Statistical analysis. Statistical analyses were performed using GraphPad Prism software (version 5.0; GraphPad Software, Inc., La Jolla, CA, USA). Differences between two groups were compared using the unpaired Student's t-test. Differences between more than two groups were compared using one-way analysis of variance followed by Tukey's multiple comparison test or Dunnett's multiple comparison test. P<0.05 was considered to indicate a statistically significant difference.
Results
Propranolol and ICI 118,551 inhibit MDA-MB-231 cell viability.
To determine the effects of different β-blockers on TNBC, MDA-MB-231 cells were treated with increasing concentrations of metoprolol, ICI 118,551 and propranolol for 24, 48 and 72 h. Cell viability was assessed using the Alamar Blue assay. Following β-blocker treatment, propranolol and ICI 118,551 were identified to exert concentration-dependent anti-viability effects against MDA-MB-231 cells, whereas the effect of metoprolol was not notable (Fig. 1A-C) . The half-maximal inhibitory concentration (IC 50 ) for propranolol was between 180 and 261.5 µM; the IC 50 for ICI 118,551 was between 86.3 and 153.5 µM; and the IC 50 for metoprolol was >400 µM (Fig. 1D) . Fig. 2A and B) , along with a decreasing distribution of cells in S phase from 28.16 to 11.94 (100 µM ICI 118,551), 12.99 (150 µM ICI 118,551), 13.17 (100 µM propranolol) and 13.32% (200 µM propranolol) (P<0.05; Fig. 2A and B) . The number of cells in G 2 /M phase was increased following treatment with 200 µM propranolol only (16.22 to 23.42%, P<0.05; Fig. 2A and B) . Following cell cycle analysis, apoptosis was also analyzed using flow cytometry with Annexin V and PI staining. The proportion of apoptotic cells was determined as the sum of the ratios of early and late apoptotic cells. Following ICI 118,551 (100 and 150 µM) and propranolol (100 and 200 µM) treatment, the apoptosis rate of MDA-MB-231 cells increased from 0.9 to 4.1 (100 µM ICI 118,551), 5.3 (150 µM ICI 118,551), 4.5 (100 µM propranolol) and 6.6% (200 µM propranolol) (P<0.05; Fig. 2C and D) . These results suggested that ICI 118,551 and propranolol inhibit the viability of MDA-MB-231 cells by arresting cell cycle progression at G 0 /G 1 and S phase and then inducing apoptosis. In addition, the effect on apoptosis induction was enhanced with increasing drug concentration.
Propranolol and ICI 118,551 downregulate the phosphorylation levels of ERK1/2 and the expression levels of COX-2.
Previous studies indicate that the mitogen-activated protein kinase (MAPK) and COX-2 signaling pathways were associated with the proliferation and apoptosis of tumor cells (33, 34) . It was therefore hypothesized that propranolol and ICI 118,551 may exert antitumor effects by regulating the factors participating in the signaling pathways. The expression levels of several proteins in these pathways were analyzed using western blot analysis. Following treatment with 100 µM propranolol and 100 µM ICI 118,551, the expression levels of COX-2 and the phosphorylation levels of p38 and ERK1/2 were not altered markedly (P>0.05; Fig. 3A and B) . Following an increase in the drug concentration (200 µM propranolol and 150 µM ICI 118,551), the expression levels of COX-2 and the phosphorylation levels of ERK1/2 decreased (P<0.05; Fig. 3A and B) , whereas phosphorylated p38 remained unchanged. These results suggested that ICI 118,551 and propranolol may inhibit the viability of MDA-MB-231 cells by targeting ERK1/2 phosphorylation and COX-2 expression.
Effect of ADRB2 SNPs on β 2 -AR expression. β 2 -AR is the main target of ICI 118,551 and propranolol. Therefore, it was investigated further whether SNPs rs1042713 and rs1042714 of ADRB2 affected the expression levels of the β 2 -AR. 293 cells were transfected with wild-type ADRB2 and mutant ADRB2 plasmids for 24, 48 and 72 h. Subsequently, total RNA was extracted and mRNA expression levels in the cells were determined using qPCR. Furthermore, total protein was extracted and analyzed using western blotting following transfection for 24 h. Compared with the wild-type group, the ADRB2 mRNA expression levels were significantly decreased in mutant groups (46AA/79GG, 46GG/79CC and 46GG/79GG) after 24 and 48 h of transfection (P<0.05; Fig. 4A ). However, after 72 h of transfection, the ADRB2 mRNA expression was significantly decreased only in the 46GG/79CC group (P<0.05; Fig. 4A ). Interestingly, compared with the wild-type group, ADRB2 mRNA expression was significantly increased in the 46GG/79GG group at 72 h. With regard to the β 2 -AR protein expression levels, no significant difference was identified between the wild-type and the mutant groups (P>0.05; Fig. 4B ). These results revealed that SNPs rs1042713 and rs1042714 of ADRB2 may affect the mRNA expression levels, but not the protein expression levels of β 2 -AR.
Effect of ADRB2 SNPs on cell viability and anti-viability effect
of ICI 118,551. The SNPs of ADRB2 were shown to affect the mRNA expression of β 2 -AR. Further study was performed to assess whether ADRB2 SNPs were able to affect cell viability and the anti-viability effect of β-blockers. 293 cells were transfected with the different plasmids for 24, 48 and 72 h. Subsequently, cell viability was detected by MTS. Following transfection, the cell viability of the five groups exhibited no significant difference (P>0.05; Fig. 5A ). In order to investigate 8 µM) . Notably, after 72 h of ICI 118,551 treatment, there was no significant difference in the IC 50 value between the four groups (P>0.05; Fig. 5B ). These results suggested that ADRB2 SNPs did not affect cell viability, but did affect the anti-viability effect of ICI 118,551.
ADRB2 SNPs may affect the regulatory function of ICI 118,551 on the ERK/COX-2 signaling pathway.
It was investigated whether β-blockers could affect ERK1/2 phosphorylation and COX-2 expression and the effect of ADRB2 SNPs. 293 cells were transfected with different plasmids and treated with 80 µM ICI 118,551 for 24 h, and the concentration of ICI 118,551 was determined on the basis of the results of previous MTS assays. The expression levels of COX-2 and p-ERK1/2 in the 46GG/79GG group were significantly increased compared with the wild-type, 46AA/79GG and 46GG/79CC groups (P<0.05; Fig. 6A and B) . Although the protein expression levels were different between the wild-type, 46AA/79GG and 46GG/79CC groups, the differences were not statistically significant (P>0.05; Fig. 6A and B) . These results revealed that the regulatory function of ICI 118,551 on COX-2 and p-ERK1/2 expression was affected by ADRB2 SNPs.
Discussion
The results of the present study indicated that propranolol and ICI 118,551 inhibited the viability of MDA-MB-231 cells by downregulating ERK1/2 phosphorylation and COX-2 expression and inducing apoptosis. Furthermore, SNPs rs1042713 and rs1042714 of ADRB2 were identified to affect the anti-viability effect of ICI 118,551, and the underlying molecular mechanism was investigated.
It was identified that the non-selective β-blocker propranolol and the selective β 2 -blocker ICI 118,551 significantly inhibited the viability of MDA-MB-231 cells, whereas the selective β 1 -blocker metoprolol did not. Similar results were reported by Chin et al (35) , who identified that colorectal cancer cells were only sensitive to ICI 118,551 and propranolol, but not atenolol (a selective β 1 -blocker), and the effects of ICI 118,551 were the most potent. However, Liu et al (36) identified that atenolol and ICI 118,551 were able to attenuate the function of epinephrine in promoting esophageal cancer cell proliferation. Different expression levels of three β-AR subtypes in various types of tumor cells may account for these conflicting results. Consistent with an in vitro study, which reported the sensitivity of MDA-MB-231 cells to propranolol (IC 50 value of 200 µM) (18) , it was identified in the present study that propranolol exerted its anti-viability effect at a concentration that was significantly higher than the peak serum concentration (0.77-1.5 µM in vivo) (37) . Notably, there is a large discrepancy of drug concentration between in vitro and in vivo models. This may be because propranolol inhibits the growth of the tumor itself in vivo, and also inhibits angiogenesis (38) and regulates immune system function (39, 40) . This multifaceted antitumor effect may be beneficial in decreasing the drug concentration in in vivo models.
The activation of the MAPK signaling pathway has been associated with the resistance of TNBC to chemotherapy (33). Huang et al (41) identified that NE stimulated the proliferation, migration and invasion of pancreatic cancer cells via the β-AR/P38/MAPK signaling pathway. Additionally, the overexpression of COX-2 has been associated with shorter relapse-free survival in stage III patients who were ER-negative (42) . Furthermore, Liu et al (36) demonstrated that epinephrine was able to stimulate the proliferation of esophageal squamous cell carcinoma cells via the β-AR/ERK/COX-2 signaling pathway. Owing to the aforementioned results mentioned, the effect of β-blockers on p38, ERK1/2 phosphorylation and COX-2 expression was investigated in MDA-MB-231 cells. The results suggested that propranolol and ICI 118,551 inhibited the activation of the ERK/COX-2 signaling pathway, but had no effect on p38 phosphorylation.
Feigelson et al (43) identified that ADRB2 SNPs were not associated with the risk of post-menopausal breast cancer; however, in the present study, it was identified that ADRB2 SNPs rs1042713 and rs1042714 may affect the response to β-blockers in the treatment of breast cancer. The results of the present study revealed that ADRB2 mRNA expression was significantly decreased in mutant haplotypes (46AA/79GG, 46GG/79CC and 46GG/79GG) after 24 and 48 h of transfection. However, there were no significant differences in β 2 -AR protein expression levels between wild-type and mutant haplotypes. It has been identified previously that codon optimality may affect the degradation rate of mRNA and the elongation rate of ribosomes, and may ultimately affect the folding rate, stability and activity of proteins (44) . SNPs rs1042713 and rs1042714 of ADRB2 may alter the degradation rate of mRNA, thereby altering the function of β 2 -AR and the response to β-blocker drugs. Marson et al (45) reported that SNPs rs1042713 and rs1042714 of ADRB2 were associated with the bronchodilator response in cystic fibrosis. In patients with chronic heart failure, Metra et al (46) identified that SNP rs1042714 determined the left ventricular ejection fraction response to carvedilol, whereas SNP rs1042713 had no such effect. Similarly, Martin et al (27) identified an association only between SNP rs1042714 and the response to β 2 -agonists in children with acute asthma. The association between the two SNPs, which may result in amino acid changes and altered response to drugs in different diseases, has been widely investigated. However, the effects of the two SNPs on tumors and on the response to β-blockers requires further investigation.
In the present study, the effect of ADRB2 SNPs on the molecular mechanism underlying the antitumor effect of β-blockers was investigated and it was identified that only the 46GG/79GG haplotype significantly impaired the inhibitory effect of ICI 118,551 on the ERK/COX-2 signaling pathway. This phenomenon may explain why the IC 50 value of ICI 118,551 was higher in the 46GG/79GG group. However, for the 46AA/79GG and 46GG/79CC haplotypes, the inhibitory effect of ICI 118,551 on the ERK/COX-2 signaling pathway did not change significantly, suggesting that other mechanisms may be involved in the effect of ADRB2 SNPs on the antitumor properties of β-blockers. Ahles et al (47) identified that variants carrying Gly 16 (46GG/79CC and 46GG/79GG) exhibited significant acceleration in response to repetitive stimulation compared with the Arg 16 Gln 27 (46AA/79CC) variant, suggesting that ADRB2 SNPs altered the activation kinetics of β 2 -AR during repetitive stimulation. The difference in activation kinetics may reflect distinct β 2 -AR conformations, and the change in activation speed may result in altered downstream signaling.
The present study had certain limitations. With regard to ADRB2 mRNA expression, it was identified that mRNA expression in the 46GG/79GG haplotype increased inexplicably, particularly following transfection for 72 h. Owing to the multifaceted antitumor effect of β-blockers, in vitro experiments may not suffice, and further verification of the antitumor effect of β-blockers on TNBC in in vivo experiments and clinical trials is required.
In summary, the results of the present study revealed that ICI 118,551 and propranolol, but not metoprolol, significantly inhibited the growth of TNBC by inhibiting cell viability, blocking cell cycle progression and inducing cell apoptosis. Furthermore, the molecular mechanism behind this effect may involve the inhibition of the ERK/COX-2 signaling pathway. It was also identified that SNPs rs1042713 and rs1042714 of ADRB2 affected the anti-viability effect of ICI 118,551. ADRB2 SNPs may alter the mRNA expression levels of β 2 -AR and the activation of the downstream signaling pathway. Additionally, ADRB2 SNPs may be involved in the response to ICI 118,551 treatment. Therefore, β-blockers may be a viable option for the treatment of TNBC, and SNPs rs1042713 and rs1042714 of ADRB2 may result in individual responses to β-blockers.
